Cargando…

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide

Secondary hormone therapy, abiraterone and enzalutamide, has improved outcomes for metastatic castration-resistant prostate cancer (mCRPC) and prolonged patients’ lives significantly. Various studies have compared the cancer-related outcomes, adverse effects, and drug-induced comorbidities in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yi-Ting, Huang, Yen-Chun, Liu, Chih-Kuan, Lee, Tian-Shyug, Chen, Mingchih, Chien, Yu-Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167063/
https://www.ncbi.nlm.nih.gov/pubmed/34084142
http://dx.doi.org/10.3389/fphar.2021.669236
_version_ 1783701617599578112
author Lin, Yi-Ting
Huang, Yen-Chun
Liu, Chih-Kuan
Lee, Tian-Shyug
Chen, Mingchih
Chien, Yu-Ning
author_facet Lin, Yi-Ting
Huang, Yen-Chun
Liu, Chih-Kuan
Lee, Tian-Shyug
Chen, Mingchih
Chien, Yu-Ning
author_sort Lin, Yi-Ting
collection PubMed
description Secondary hormone therapy, abiraterone and enzalutamide, has improved outcomes for metastatic castration-resistant prostate cancer (mCRPC) and prolonged patients’ lives significantly. Various studies have compared the cancer-related outcomes, adverse effects, and drug-induced comorbidities in patients with mCRPC who are treated with abiraterone or enzalutamide. However, few studies have explored associations between survival and comorbidities or comprehensive analyzed newly developed comorbidities during and after secondary hormone therapy. We attempted to clarify whether the Charlson comorbidity index (CCI) overall or itemized is predictive for overall survival, and we compared newly developed comorbidities between abiraterone and enzalutamide groups. We extracted data about expenses and comorbidities for patients who have mCRPC, received abiraterone and enzalutamide and met pre-examination operation criteria between September 2016 and December 2017 from the Taiwan National Health Insurance database. A total of 1153 patients with mCRPC who received abiraterone (n = 782) or enzalutamide (n = 371) with or without previous chemotherapy were included. We used the propensity score to match confounding factors, including age, pre-existing comorbidities, and precipitating factors for comorbidity (e.g., hypertension, hyperlipidemia), to eliminate selection bias in the comparison of newly developed comorbidities. Cox regression analysis was used for overall survival. We found that enzalutamide is superior to abiraterone with regard to overall survival. Our study revealed that there is no statistically significant difference in development of new comorbidities between abiraterone and enzalutamide group. Moreover, the CCI score, rather than any single item of the CCI, was a statistically significant predictor for overall survival.
format Online
Article
Text
id pubmed-8167063
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81670632021-06-02 Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide Lin, Yi-Ting Huang, Yen-Chun Liu, Chih-Kuan Lee, Tian-Shyug Chen, Mingchih Chien, Yu-Ning Front Pharmacol Pharmacology Secondary hormone therapy, abiraterone and enzalutamide, has improved outcomes for metastatic castration-resistant prostate cancer (mCRPC) and prolonged patients’ lives significantly. Various studies have compared the cancer-related outcomes, adverse effects, and drug-induced comorbidities in patients with mCRPC who are treated with abiraterone or enzalutamide. However, few studies have explored associations between survival and comorbidities or comprehensive analyzed newly developed comorbidities during and after secondary hormone therapy. We attempted to clarify whether the Charlson comorbidity index (CCI) overall or itemized is predictive for overall survival, and we compared newly developed comorbidities between abiraterone and enzalutamide groups. We extracted data about expenses and comorbidities for patients who have mCRPC, received abiraterone and enzalutamide and met pre-examination operation criteria between September 2016 and December 2017 from the Taiwan National Health Insurance database. A total of 1153 patients with mCRPC who received abiraterone (n = 782) or enzalutamide (n = 371) with or without previous chemotherapy were included. We used the propensity score to match confounding factors, including age, pre-existing comorbidities, and precipitating factors for comorbidity (e.g., hypertension, hyperlipidemia), to eliminate selection bias in the comparison of newly developed comorbidities. Cox regression analysis was used for overall survival. We found that enzalutamide is superior to abiraterone with regard to overall survival. Our study revealed that there is no statistically significant difference in development of new comorbidities between abiraterone and enzalutamide group. Moreover, the CCI score, rather than any single item of the CCI, was a statistically significant predictor for overall survival. Frontiers Media S.A. 2021-05-18 /pmc/articles/PMC8167063/ /pubmed/34084142 http://dx.doi.org/10.3389/fphar.2021.669236 Text en Copyright © 2021 Lin, Huang, Liu, Lee, Chen and Chien. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lin, Yi-Ting
Huang, Yen-Chun
Liu, Chih-Kuan
Lee, Tian-Shyug
Chen, Mingchih
Chien, Yu-Ning
Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
title Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
title_full Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
title_fullStr Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
title_full_unstemmed Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
title_short Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
title_sort treatment-emergent co-morbidities and survival in patients with metastatic castration-resistant prostate cancer receiving abiraterone or enzalutamide
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167063/
https://www.ncbi.nlm.nih.gov/pubmed/34084142
http://dx.doi.org/10.3389/fphar.2021.669236
work_keys_str_mv AT linyiting treatmentemergentcomorbiditiesandsurvivalinpatientswithmetastaticcastrationresistantprostatecancerreceivingabirateroneorenzalutamide
AT huangyenchun treatmentemergentcomorbiditiesandsurvivalinpatientswithmetastaticcastrationresistantprostatecancerreceivingabirateroneorenzalutamide
AT liuchihkuan treatmentemergentcomorbiditiesandsurvivalinpatientswithmetastaticcastrationresistantprostatecancerreceivingabirateroneorenzalutamide
AT leetianshyug treatmentemergentcomorbiditiesandsurvivalinpatientswithmetastaticcastrationresistantprostatecancerreceivingabirateroneorenzalutamide
AT chenmingchih treatmentemergentcomorbiditiesandsurvivalinpatientswithmetastaticcastrationresistantprostatecancerreceivingabirateroneorenzalutamide
AT chienyuning treatmentemergentcomorbiditiesandsurvivalinpatientswithmetastaticcastrationresistantprostatecancerreceivingabirateroneorenzalutamide